Literature DB >> 21852761

Contemporary management of vascular Ehlers-Danlos syndrome.

Ying Wei Lum1, Benjamin S Brooke, James H Black.   

Abstract

PURPOSE OF REVIEW: Vascular Ehlers-Danlos syndrome (EDS) results from mutations in the formation of type III collagen. This leads to various potentially lethal complications including rupture of the arterial vessels, intestinal organs, and the uterus. This review summarizes recent cohort studies that have improved our medical and surgical management of complications associated with vascular EDS. RECENT
FINDINGS: Vascular EDS is associated with a shortened overall survival due to potential complications, namely loss of connective tissue integrity in blood vessels and increased risk of arterial rupture. The traditional approach has been to treat such complications conservatively unless they are life threatening. There have been challenges to this treatment paradigm based on recent reports. Treatment with the beta blocker Celiprolol was shown in a randomized study to be associated with a three-fold decrease in arterial rupture in vascular EDS patients. Furthermore, it was shown by observational studies that elective surgical repair of blood vessels at risk of rupture may be safely undertaken at tertiary referral centers that have expertise in managing connective tissue disorders. Novel approaches using endovascular therapy with coil embolization have also been attempted with good results in the treatment of ruptured pseudoaneurysms, visceral aneurysms, and carotid-cavernous fistulas.
SUMMARY: New evidence-based treatments have greatly expanded the medical and surgical management options for patients with EDS. These patients are best managed by multidisciplinary teams of interventionalists, cardiologists, and geneticists in tertiary centers with expertise in managing connective tissue disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21852761     DOI: 10.1097/HCO.0b013e32834ad55a

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  12 in total

1.  Heart transplantation in the Ehlers-Danlos syndrome.

Authors:  Stephanie M Reinhold; Brian Lima; Adnan Khalid; Gonzalo V Gonzalez-Stawinski; Robert C Stoler; Shelley A Hall; Themistokles Chamogeorgakis
Journal:  Proc (Bayl Univ Med Cent)       Date:  2015-10

2.  Clinical utility gene card for: Ehlers-Danlos syndrome types I-VII and variants - update 2012.

Authors:  Karin Mayer; Ingo Kennerknecht; Beat Steinmann
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

3.  Molecular diagnosis in vascular Ehlers-Danlos syndrome predicts pattern of arterial involvement and outcomes.

Authors:  Sherene Shalhub; James H Black; Alana C Cecchi; Zhi Xu; Ben F Griswold; Hazim J Safi; Dianna M Milewicz; Nazli B McDonnell
Journal:  J Vasc Surg       Date:  2014-03-18       Impact factor: 4.268

Review 4.  Neurological manifestations of Ehlers-Danlos syndrome(s): A review.

Authors:  Marco Castori; Nicol C Voermans
Journal:  Iran J Neurol       Date:  2014-10-06

5.  Vascular Ehlers-Danlos syndrome without the characteristic facial features: a case report.

Authors:  Ryota Inokuchi; Hideaki Kurata; Kiyoshi Endo; Yoichi Kitsuta; Susumu Nakajima; Atsushi Hatamochi; Naoki Yahagi
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

6.  Vascular type Ehlers-Danlos syndrome is associated with platelet dysfunction and low vitamin D serum concentration.

Authors:  Albert Busch; Sabine Hoffjan; Frauke Bergmann; Birgit Hartung; Helena Jung; Daniela Hanel; Andeas Tzschach; Janos Kadar; Yskert von Kodolitsch; Christoph-Thomas Germer; Heiner Trobisch; Erwin Strasser; René Wildenauer
Journal:  Orphanet J Rare Dis       Date:  2016-08-03       Impact factor: 4.123

Review 7.  A Review of the Genetics of Intracranial Berry Aneurysms and Implications for Genetic Counseling.

Authors:  Emma Hitchcock; William T Gibson
Journal:  J Genet Couns       Date:  2016-10-14       Impact factor: 2.537

8.  Celiprolol: A Unique Selective Adrenoceptor Modulator.

Authors:  James J Nawarskas; Angela Cheng-Lai; William H Frishman
Journal:  Cardiol Rev       Date:  2017 Sep/Oct       Impact factor: 2.644

9.  Incidentalome from Genomic Sequencing: A Barrier to Personalized Medicine?

Authors:  Saumya Shekhar Jamuar; Jyn Ling Kuan; Maggie Brett; Zenia Tiang; Wilson Lek Wen Tan; Jiin Ying Lim; Wendy Kein Meng Liew; Asif Javed; Woei Kang Liew; Hai Yang Law; Ee Shien Tan; Angeline Lai; Ivy Ng; Yik Ying Teo; Byrappa Venkatesh; Bruno Reversade; Ene Choo Tan; Roger Foo
Journal:  EBioMedicine       Date:  2016-02-04       Impact factor: 8.143

10.  Increased augmentation index in patients with Ehlers-Danlos syndrome.

Authors:  Maurice Roeder; Sira Thiel; Frederic Baumann; Noriane A Sievi; Marianne Rohrbach; Malcolm Kohler; Thomas Gaisl
Journal:  BMC Cardiovasc Disord       Date:  2020-09-15       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.